Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IMMUTEP LIMITED Capital/Financing Update 2008

Jan 17, 2008

65122_rns_2008-01-17_71f1cc60-2108-4fad-8f65-e98d22b17f65.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

ABN 90 009 237 889

==> picture [193 x 52] intentionally omitted <==

ASX ANNOUNCEMENT

TIMETABLE

Non-Renounceable Rights Issue of Options Pro rata offer of 1 option for each 3 shares held at the record date.

Friday 18 January 2008, Sydney, Australia: Prima Biomed Limited (ASX: PRR) advises the following timetable will apply to the non-renounceable rights issue (pro rata offer) of options under the prospectus lodged with ASIC and ASX today.

TIMETABLE

Lodgement of Prospectus and notice to option holders of recorddate Friday 18 January 2008
Shares quoted 'ex’ rights Tuesday 22 January 2008
Record Date (for determining entitlement to participate in pro rataoffer) Tuesday 29 January 2008(5pm Perth WA time)
Dispatch of Prospectus to Shareholders Monday 4 February 2008
Closing date of pro-rata offer Monday 18 February 2008
Pro-rata offer options quoted on a deferred settlement basis andNotification of under subscriptions for the pro-rata offer Thursday 21 February 2008
Dispatch date Tuesday 26 February 2008

For further information:

Company Enquiries Ata Gokyildirim 0408 685 548

About Prima Biomed Ltd

Prima Biomed (ASX: PRR) is a biotechnology company based in Sydney, Australia. The Company is focused on technologies in the fields of immunology and cancer immunotherapy. Prima is focused on developing a dendritic-cell based immunotherapy targeting mucin-1 tumour expressed antigen. Prima’s lead product, CVac™ has completed Phase IIa clinical development in Ovarian Cancer.

Offers of Prima Biomed Ltd’s options are made in the Prospectus dated 18 January 2008 which has been lodged with the Australian Securities and Investments Commission. Anyone wishing to acquire Prima Biomed Ltd options who is eligible to participate in the pro-rata offer will need to complete an Entitlement and Acceptance Application Form that will accompany the Prospectus. Only recipients of an invitation to participate in the placement offer also made in the Prospectus are eligible to apply for options under the placement offer.

Prima BioMed Ltd , Suite 1705, 109 Pitt St, Sydney NSW 2000 AUSTRALIA Ph: 0411 563 463 www.primabiomed.com.au